: This investor crushes his fund’s benchmark with these 10 stocks
- ByMarketWatch-
Neal Kaufman at the Baron Health Care Fund seeks out companies with durable advantages and recurring revenue.
Symbol | Exchange | Currency |
|---|
Neal Kaufman at the Baron Health Care Fund seeks out companies with durable advantages and recurring revenue.
Guardant Health (GH) has initiated the Observation of ResiduAl Cancer with Liquid biopsy Evaluation ((ORACLE)) study, a 1,000-patient prospective, observational, study designed...
Guardant Health Inc (NASDAQ: GH) has decided not to pursue a potential acquisition of NeoGenomics Inc (NASDAQ: NEO), Bloomberg reported citing people familiar with the...
We’re in the thick of big tech earnings right now and also had to deal with a Fed statement on Wednesday, so it’s no surprise that today’s session saw an...
Exact Sciences (NASDAQ:EXAS) EXAS is the $19 billion leader in proactive cancer diagnostics with the Cologuard screening kit, which the majority of healthcare providers are...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Strong Buy | Buy | Sell | Neutral |
| Technical Indicators | Neutral | Strong Sell | Strong Buy | Strong Sell | Sell |
| Summary | Neutral | Neutral | Strong Buy | Strong Sell | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 55.21 | 55.22 | 54.37 | +0.74 | +1.36% | 18.23M | NASDAQ | |||
| 148.76 | 149.17 | 146.55 | +2.21 | +1.51% | 74.66M | NASDAQ | |||
| 140.66 | 140.82 | 138.80 | -1.68 | -1.18% | 9.51M | NYSE | |||
| 2,864.70 | 2,873.30 | 2,852.00 | +9.2 | +0.32% | 996.72K | NASDAQ | |||
| 339.99 | 342.46 | 337.28 | +4.65 | +1.39% | 18.70M | NASDAQ | |||
| 177.31 | 178.00 | 176.26 | +0.49 | +0.28% | 1.39M | NYSE | |||
| 639.00 | 641.00 | 632.30 | +1.03 | +0.16% | 6.35M | NASDAQ | |||
| 124.29 | 125.14 | 122.95 | +0.76 | +0.62% | 916.54K | NYSE | |||
| 49.29 | 49.35 | 48.93 | +0.69 | +1.42% | 4.47M | NYSE | |||
| 158.77 | 158.89 | 156.82 | +2.43 | +1.55% | 444.00K | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 11.66 | 11.83 | 10.03 | +1.59 | +15.79% | 67.84M | NASDAQ | |||
| 33.18 | 34.29 | 33.09 | -0.39 | -1.16% | 564.36K | NASDAQ | |||
| 19.31 | 19.49 | 19.07 | +0.24 | +1.26% | 12.67M | NYSE | |||
| 216.24 | 216.71 | 213.46 | +0.64 | +0.30% | 938.01K | NYSE |
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.